Entries by James Halifax

,

Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with Psilocybin

Compass Pathways (Nasdaq: CMPS) has announced the launch of a brand new psychedelic clinical trial, using psilocybin (the active ingredient in magic mushrooms) to treat PTSD, and there are multiple reasons to be excited about it. The Phase-2 clinical trial will use Comp 360, Compass Pathways’ proprietary synthetic crystalline psilocybin, paired with talk psychotherapy, in […]